other cardiovascular — Sales to Customers
Products & Services · Sales to CustomersJohnson & Johnson other cardiovascular — Sales to Customers remained flat by 0.0% to $190.00M in Q4 2024 compared to the prior quarter. Year-over-year, this metric grew by 6.7%, from $178.00M to $190.00M. Over 2 years (FY 2022 to FY 2024), other cardiovascular — Sales to Customers shows an upward trend with a 7.0% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates growing market adoption or successful commercialization of specialized cardiovascular products, while a decrease may signal market saturation or competitive pressure in these niche areas.
Detailed definition
This metric represents the total revenue generated from the sale of cardiovascular medical devices and related products...
Peer comparison
Peers in the medical device industry typically report similar revenue streams under specialized cardiovascular or 'other' medical technology segments.
jnj_segment_other_cardiovascular_sales_to_customersHistorical Data
| FY'22 | FY'23 | FY'24 | |
|---|---|---|---|
| Value | $664.00M | $712.00M | $760.00M |
| YoY Change | — | +7.2% | +6.7% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Johnson & Johnson's other cardiovascular — sales to customers?
- Johnson & Johnson (JNJ) reported other cardiovascular — sales to customers of $190.00M in Q4 2024.
- How has Johnson & Johnson's other cardiovascular — sales to customers changed year-over-year?
- Johnson & Johnson's other cardiovascular — sales to customers increased by 6.7% year-over-year, from $178.00M to $190.00M.
- What is the long-term trend for Johnson & Johnson's other cardiovascular — sales to customers?
- Over 2 years (2022 to 2024), Johnson & Johnson's other cardiovascular — sales to customers has grown at a 7.0% compound annual growth rate (CAGR), from $664.00M to $760.00M.
- What does other cardiovascular — sales to customers mean?
- The total revenue generated from the sale of specialized or secondary cardiovascular medical products.